• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

为系统性硬化症患者的纵向随访设定国际标准:基于德尔菲法的核心临床特征专家共识。

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features.

机构信息

Department of Rheumatology, Oslo University Hospital, Oslo, Norway.

Department of Rheumatology, University of Zurich, Zurich, Switzerland.

出版信息

RMD Open. 2019 Mar 4;5(1):e000826. doi: 10.1136/rmdopen-2018-000826. eCollection 2019.

DOI:10.1136/rmdopen-2018-000826
PMID:30997150
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6446182/
Abstract

BACKGROUND

Systemic sclerosis (SSc) is a severe, progressive multiorgan disease but to date, there are no established standardised international guidelines for follow-up of patients with SSc. The goal of this project was to develop an expert consensus for annual systematic investigations in patients with SSc to enhance their standard-of-care.

MATERIAL AND METHODS

The Delphi method was applied. All SSc experts from the European Scleroderma Trials and Research group network and the Scleroderma Clinical Trial Consortium were invited to participate. All experts were asked to answer questionnaires in five Delphi steps to determine the domains of interest and tools for each domain for an annual systematic assessment of patients with SSc. Each item was rated on a scale between 0% and 100% (not and very important), and parameters rated >80% by more than 75% of the experts were regarded as acceptable.

RESULTS

In total, 157 experts worldwide participated with 71.3% experts seeing >50 patients with SSc annually. In the first round, 23 domains and 204 tools were suggested. After five Delphi steps, experts agreed on 10 domains including (1) Raynaud's phenomenon; (2) Digital ulcers; (3) Skin and mucosa; (4) Lung; (5); Heart; (6) GI domain, (7) Renal; (8) Musculoskeletal; (9) Laboratory and (10) Treatment. Overall, 55 tools were identified including clinical assessments, laboratory measurements and imaging or functional investigations.

CONCLUSION

Through five Delphi steps with world leading experts, a consensus was established on strongly suggested tools for a minimum annual systemic assessment of organ involvement in SSc. This work should enhance the standardisation and homogenisation of the practices.

摘要

背景

系统性硬化症(SSc)是一种严重的、进行性的多器官疾病,但迄今为止,尚无针对 SSc 患者随访的既定国际标准指南。本项目的目标是制定 SSc 患者年度系统检查的专家共识,以提高其护理标准。

材料和方法

采用德尔菲法。邀请欧洲硬皮病试验和研究组网络和硬皮病临床试验联盟的所有 SSc 专家参与。要求所有专家在五个德尔菲步骤中回答问卷,以确定感兴趣的领域和每个领域的工具,用于对 SSc 患者进行年度系统评估。每个项目的评分范围为 0%至 100%(不重要和非常重要),超过 75%的专家评分>80%的参数被认为是可接受的。

结果

全球共有 157 名专家参与,其中 71.3%的专家每年诊治>50 名 SSc 患者。在第一轮中,提出了 23 个领域和 204 种工具。经过五个德尔菲步骤,专家们就 10 个领域达成一致,包括(1)雷诺现象;(2)指溃疡;(3)皮肤和粘膜;(4)肺;(5)心脏;(6)胃肠道;(7)肾脏;(8)肌肉骨骼;(9)实验室和(10)治疗。总体而言,确定了 55 种工具,包括临床评估、实验室测量以及影像学或功能检查。

结论

通过与世界领先专家进行的五个德尔菲步骤,就 SSc 器官受累的最低年度系统评估强烈建议的工具达成了共识。这项工作应增强实践的标准化和同质化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be1e/6446182/d462b0fc51e7/rmdopen-2018-000826f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be1e/6446182/373f2ff0af38/rmdopen-2018-000826f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be1e/6446182/d462b0fc51e7/rmdopen-2018-000826f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be1e/6446182/373f2ff0af38/rmdopen-2018-000826f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be1e/6446182/d462b0fc51e7/rmdopen-2018-000826f02.jpg

相似文献

1
Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features.为系统性硬化症患者的纵向随访设定国际标准:基于德尔菲法的核心临床特征专家共识。
RMD Open. 2019 Mar 4;5(1):e000826. doi: 10.1136/rmdopen-2018-000826. eCollection 2019.
2
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise.制定系统性硬化症修订分类标准的项目:共识性工作的结果。
Arthritis Care Res (Hoboken). 2012 Mar;64(3):351-7. doi: 10.1002/acr.20679.
3
A Delphi exercise and cluster analysis to aid in the development of potential classification criteria for systemic sclerosis using SSc experts and databases.德尔菲法和聚类分析辅助系统性硬化症专家和数据库制定潜在分类标准。
Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):24-30. Epub 2013 Apr 2.
4
Update of EULAR recommendations for the treatment of systemic sclerosis.EULAR 系统性硬皮病治疗推荐更新。
Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9.
5
Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis.专家共识:对疑似系统性硬化症相关肺动脉高压进行右心导管检查:一项聚类分析德尔菲共识研究。
Ann Rheum Dis. 2014 Jan;73(1):191-7. doi: 10.1136/annrheumdis-2012-202567. Epub 2013 Jan 24.
6
Development of a provisional core set of response measures for clinical trials of systemic sclerosis.系统性硬化症临床试验临时核心反应指标集的制定。
Ann Rheum Dis. 2008 May;67(5):703-9. doi: 10.1136/ard.2007.078923. Epub 2007 Sep 24.
7
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).系统性硬化症临床试验中的反应测量:系统性硬化症综合反应指数 (CRISS) 和与系统性硬化症相关的肺动脉高压结局测量 (EPOSS)。
J Rheumatol. 2009 Oct;36(10):2356-61. doi: 10.3899/jrheum.090372.
8
The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis.欧洲儿科风湿病学会/美国风湿病学会/欧洲抗风湿病联盟青少年系统性硬化症临时分类标准
Arthritis Rheum. 2007 Mar 15;57(2):203-12. doi: 10.1002/art.22551.
9
Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique.TNFα 拮抗剂在硬皮病治疗中的作用如何?EUSTAR 采用 Delphi 技术的专家共识发展。
Clin Exp Rheumatol. 2011 Mar-Apr;29(2 Suppl 65):S40-5. Epub 2011 May 12.
10
Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG).硬皮病最佳实践:加拿大硬皮病研究组(CSRG)内 SSc 中心实践差异分析。
Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S38-43. Epub 2012 May 29.

引用本文的文献

1
Deep hierarchical subtyping of multi-organ systemic sclerosis trajectories - a EUSTAR study.多器官系统性硬化症病程的深度分层亚型分析——一项欧洲抗风湿病联盟系统性硬化症标准治疗管理委员会(EUSTAR)研究
NPJ Digit Med. 2025 Sep 1;8(1):563. doi: 10.1038/s41746-025-01962-y.
2
Cardiac Involvement and Heart Failure Staging in Patients with Systemic Sclerosis Without Pulmonary Arterial Hypertension.无肺动脉高压的系统性硬化症患者的心脏受累情况及心力衰竭分期
J Clin Med. 2025 Mar 24;14(7):2211. doi: 10.3390/jcm14072211.
3
Myocardial Disease in Systemic Sclerosis: Recent Updates and Clinical Implications.

本文引用的文献

1
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.系统性硬皮病相关间质性肺病 - 个体化免疫抑制治疗和肺功能病程:EUSTAR 组的结果。
Arthritis Res Ther. 2018 Jan 30;20(1):17. doi: 10.1186/s13075-018-1517-z.
2
Mapping and predicting mortality from systemic sclerosis.系统性硬化症患者死亡率的预测与评估。
Ann Rheum Dis. 2017 Nov;76(11):1897-1905. doi: 10.1136/annrheumdis-2017-211448. Epub 2017 Aug 23.
3
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
系统性硬化症中的心肌病:最新进展与临床意义
Curr Cardiol Rep. 2025 Jan 4;27(1):3. doi: 10.1007/s11886-024-02164-w.
4
Arthritis in patients with very early systemic sclerosis: a comprehensive clinical and prognostic analysis.极早期系统性硬化症患者的关节炎:一项全面的临床与预后分析
Rheumatology (Oxford). 2025 Mar 1;64(3):1243-1250. doi: 10.1093/rheumatology/keae247.
5
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort.特发性炎症性肌病患者伴或不伴进行性纤维化表型的间质性肺病:一项大型多中心队列研究的数据。
RMD Open. 2023 Aug;9(3). doi: 10.1136/rmdopen-2023-003121.
6
Serum Biomarkers in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.结缔组织病相关肺动脉高压的血清生物标志物。
Int J Mol Sci. 2023 Feb 20;24(4):4178. doi: 10.3390/ijms24044178.
7
Quality Measures in Systemic Sclerosis.系统性硬化症的质量指标
Diagnostics (Basel). 2023 Feb 4;13(4):579. doi: 10.3390/diagnostics13040579.
8
Latent trajectory modelling of pulmonary artery pressure in systemic sclerosis: a retrospective cohort study.系统性硬皮病肺动脉压的潜在轨迹建模:一项回顾性队列研究。
RMD Open. 2022 Dec;8(2). doi: 10.1136/rmdopen-2022-002673.
9
Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography.使用高分辨率计算机断层扫描诊断和监测系统性硬化症相关间质性肺病
J Scleroderma Relat Disord. 2022 Oct;7(3):168-178. doi: 10.1177/23971983211064463. Epub 2022 Jan 3.
10
Systemic sclerosis in the time of COVID-19.新冠疫情时期的系统性硬化症
Lancet Rheumatol. 2022 Aug;4(8):e566-e575. doi: 10.1016/S2665-9913(22)00130-8. Epub 2022 Jul 21.
尼达尼布治疗系统性硬化症相关间质性肺病的随机、安慰剂对照临床试验(SENSCIS™)设计
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):75-81. Epub 2017 Jun 29.
4
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.用于系统性硬化症临床试验的改良罗德南皮肤评分的标准化。
J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.
5
Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group.系统性硬化症的功能障碍及其预测因素:EUSTAR 组的 DeSScipher 项目研究。
Rheumatology (Oxford). 2018 Mar 1;57(3):441-450. doi: 10.1093/rheumatology/kex182.
6
Systemic sclerosis.系统性硬化症。
Lancet. 2017 Oct 7;390(10103):1685-1699. doi: 10.1016/S0140-6736(17)30933-9. Epub 2017 Apr 13.
7
Recommendations for patient engagement in guideline development panels: A qualitative focus group study of guideline-naïve patients.患者参与指南制定小组的建议:一项针对初次接触指南患者的定性焦点小组研究。
PLoS One. 2017 Mar 20;12(3):e0174329. doi: 10.1371/journal.pone.0174329. eCollection 2017.
8
Update of EULAR recommendations for the treatment of systemic sclerosis.EULAR 系统性硬皮病治疗推荐更新。
Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9.
9
Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.系统性硬化症早期器官表现的发病率及危险因素:一项欧洲硬皮病研究与治疗协会(EUSTAR)的纵向研究
PLoS One. 2016 Oct 5;11(10):e0163894. doi: 10.1371/journal.pone.0163894. eCollection 2016.
10
Systemic sclerosis.系统性硬化症。
Nat Rev Dis Primers. 2015 Apr 23;1:15002. doi: 10.1038/nrdp.2015.2.